YouJizz porno atasehir escort bostanci escort erenkoy escort goztepe escort kadikoy Escort kartal Escort maltepe Escort suadiye Escort uskudar Escort umraniye Escort kartal escort bostanci escort atasehir escort kadikoy escort kurtkoy escort tuzla escort erenkoy escort beykoz escort umraniye escort pendik escort kadikoy escort maltepe escort antalya escort konya escort

Market Research Reports and Industry Reports

Multiple Sclerosis [2016]: Bulletin #3


This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche reporting that a German patient with MS has developed progressive multifocal leukoencephalopathy (PML) following three years of treatment with Tysabri (natalizumab; Biogen) and one dose of Ocrevus (ocrelizumab); Merck Group announcing that the European Medicine Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for approval of Mavenclad (cladribine) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity, and presenting new data on cladribines mechanism of action; and The European Medicines Agencys (EMA) provisionally restricting the use of Zinbryta (daclizumab; Biogen/AbbVie) due to a patients death from liver injury (fulminant liver failure), to patients with highly active relapsing disease that has failed to respond to certain other treatments, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines.

Business Questions:

Do KOLs believe that Ocrevus was the cause of this case of PML, or are other factors at play?
What impact will the news of this case of PML have on the prescribing of Ocrevus in the US, and will the news cause any change to patient monitoring requirements?
Was the FDA right to include a warning of the risk of PML on Ocrevus label, despite no cases of PML being seen in the pre-approval setting?
What has been the reaction to the recommendation for approval of cladribine in Europe, and will Merck Groups new data for cladribine dispel concerns about increased risk of malignancy?
How concerned are KOLs about patient segmentation and eligibility for cladribine?
Will Merck Group be able to leverage cladribines mechanism of action when it comes to differentiating it compared to other treatments?
Assuming full approval, where do KOLs see cladribine being used in the MS treatment paradigm, and which products are likely to lose market share?
Do KOLs believe that the EMAs decision to restrict the use of Zinbryta in Europe was justified?
What impact will the EMAs restriction have on the prescribing of Zinbryta in the US and Europe, and will the restriction be lifted any time soon?

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2017, provides an overview

USD 2500View Report

Global Pyrotechnic Multiple Carriage Market Professional Survey Report 2017

This report studies Pyrotechnic Multiple Carriage in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions,

USD 3500View Report

Multiple Sclerosis [2017]

How will Ocrevus reshape the MS treatment landscape A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold Key opinion

USD 8145View Report

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage

USD 3995View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

+91 9987 2952 42


  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE


We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube